ArticleActas espanolas de psiquiatria2026
Associations Between Depression Severity, Antidepressant Use, and Metabolic Syndrome Components Among Chinese Adults: A Cross-Sectional Study Based on Historical Medical Records.
Article in Actas espanolas de psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression affects approximately 280 million people globally and often co-occurs with metabolic syndrome (MetS), a cluster of cardiometabolic risks that increase cardiovascular and diabetes events. This study investigates the associations among depression severity, antidepressant use and MetS components in Chinese adults.
methodsIn this cross-sectional study from a Chinese hospital (2018-2025), electronic medical records of 585 adults (aged ≥18 years, 61.54% female) were analysed using convenience sampling. Depression severity was assessed via Patient Health Questionnaire-9 (PHQ-9) scores (normal: 0-4; mild: 5-9; moderate: 10-14; severe: 15-27). MetS was defined in accordance with the National Cholesterol Education Program Adult Treatment Panel III criteria (≥three components: hypertension ≥130/85 mmHg, triglycerides >150 mg/dL, high-density lipoprotein cholesterol (HDL-C) <40/50 mg/dL, waist circumference >102/88 cm for men/women and glucose ≥100 mg/dL). Logistic regression was applied to evaluate associations, including serotonin reuptake inhibitors (SSRIs) versus serotonin-norepinephrine reuptake inhibitors (SNRIs).
resultsIn this hospital-based cohort, patients with severe depression exhibited a substantially increased odds for clustered MetS (adjusted odds ratio [OR] = 13.461, 95% confidence interval [CI]: 2.461-253.037, p = 0.015 for one MetS component and OR = 2.129, 95% CI: 1.080-4.130, p = 0.027 for two components). Severe depressive symptoms were significantly associated with multiple MetS components, specifically hyperglycaemia (adjusted OR = 2.022, 95% CI: 1.033-4.068, p = 0.043), increased triglycerides (adjusted OR = 2.460, 95% CI: 1.304-4.661, p = 0.005) and reduced HDL-C (adjusted OR = 2.653, 95% CI: 1.397-5.102, p = 0.003). Antidepressant use increased MetS odds (central obesity OR = 3.098, 95% CI: 2.098-4.614, p < 0.001; hyperglycaemia OR = 2.312, 95% CI: 1.566-3.446, p < 0.001), with SSRIs (95.2%, n = 317) being predominant over SNRIs (4.8%, n = 16) but having similar metabolic impacts in subgroups.
conclusionsDepression severity and antidepressant use are significantly associated with individual components of MetS and their clustering, underscoring the need for personalised metabolic screening in affected patients. Recognising and addressing metabolic abnormalities in individuals with depression are essential to optimise treatment outcomes and mitigate long-term cardiometabolic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.